Intra-Tumour Signalling Entropy Determines Clinical Outcome in Breast and Lung Cancer

PLoS Computational Biology

Volumn 11, Issue 3, 2015, Pages

  Banerji, Christopher R S ^a,b,c   Severini, Simone ^b   Caldas, Carlos ^d   Teschendorff, Andrew E ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; CELL PROLIFERATION; DISEASES; GENE EXPRESSION; STEM CELLS; TUMORS;

BREAST CANCER; CANCER STEM CELLS; CELL-BE; CELL/B.E; CELL/BE; CLINICAL OUTCOME; LUNG CANCER; SMALL POPULATION; TUMOR HETEROGENEITY; TUMOUR CELLS;

ENTROPY;

DOXORUBICIN; ESTROGEN RECEPTOR; SALIRASIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BMP2 GENE; BREAST CANCER; BREAST CARCINOGENESIS; CADM1 GENE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CELL HETEROGENEITY; CELLS BY BODY ANATOMY; CONTROLLED STUDY; CTNNB1 GENE; DOWN REGULATION; ENTROPY; EZH2 GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PROBABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SIGNAL TRANSDUCTION; SIGNALLING ENTROPY; SIGNALLING ENTROPY PROGNOSTIC SCORE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; BIOLOGY; BREAST NEOPLASMS; LUNG NEOPLASMS; METABOLISM; PHYSIOLOGY; PROGNOSIS;

BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; ENTROPY; FEMALE; HUMANS; LUNG NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84926373594     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004115     Document Type: Article

References (66)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–11. doi: 10.1038/35102167 11689955
2. Stingl J, Caldas C, (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7: 791–9. doi: 10.1038/nrc2212 17851544
3. Shackleton M, Quintana E, Fearon ER, Morrison SJ, (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822–9. doi: 10.1016/j.cell.2009.08.017 19737509
4. Nowell PC, (1976) The clonal evolution of tumor cell populations. Science 194: 23–8. doi: 10.1126/science.959840 959840
5. Heppner GH, (1984) Tumor heterogeneity. Cancer Res 44: 2259–65. 6372991
6. Fidler IJ, Hart IR, (1982) Biological diversity in metastatic neoplasms: origins and implications. Science 217: 998–1003. doi: 10.1126/science.7112116 7112116
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983–8. doi: 10.1073/pnas.0530291100 12629218
8. Pinto CA, Widodo E, Waltham M, Thompson EW, (2013) Breast cancer stem cells and epithelial mesenchymal plasticity—implications for chemoresistance. Cancer Lett 341: 56–62. doi: 10.1016/j.canlet.2013.06.003 23830804
9. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106: 13820–5. doi: 10.1073/pnas.0905718106 19666588
10. de Beca FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, et al. (2013) Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 66: 187–91. doi: 10.1136/jclinpath-2012-201169 23112116
11. Bruna A, Greenwood W, Le Quesne J, Teschendorff A, Miranda-Saavedra D, Rueda OM, et al. (2012) TGF-beta induces the formation of tumour-initiating cells in claudinlow breast cancer. Nat Commun 3: 1055. doi: 10.1038/ncomms2039 22968701
12. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499–507. doi: 10.1038/ng.127 18443585
13. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG, (2009) An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res 15: 6386–90. doi: 10.1158/1078-0432.CCR-09-1105 19808871
14. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68. doi: 10.1186/bcr2635 20813035
15. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. (2010) Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 107: 15449–54. doi: 10.1073/pnas.1004900107 20713713
16. Banerji CRS, Miranda-Saavedra D, Severini S, Widschwendter M, Enver T, Zhou JX, et al. (2013) Cellular network entropy as the energy potential in waddington’s differentiation landscape. Sci Rep 3: 3039. doi: 10.1038/srep03039 24154593
17. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883–92. doi: 10.1056/NEJMoa1113205 22397650
18. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38: 468–73. doi: 10.1038/ng1768 16565718
19. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz J L A, Kinzler KW, (2013) Cancer genome landscapes. Science 339: 1546–58. doi: 10.1126/science.1235122 23539594
20. West J, Bianconi G, Severini S, Teschendorff AE, (2012) Differential network entropy reveals cancer system hallmarks. Sci Rep 2: 802. doi: 10.1038/srep00802 23150773
21. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11–30. doi: 10.3322/caac.21166 23335087
22. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379: 823–32. doi: 10.1016/S0140-6736(11)61941-7 22285053
23. Bergot E, Levallet G, Campbell K, Dubois F, Lechapt E, Zalcman G, (2013) Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev 22: 565–76. doi: 10.1183/09059180.00007113 24293473
24. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–6. doi: 10.1038/415530a 11823860
25. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009. doi: 10.1056/NEJMoa021967 12490681
26. Andre F, Delaloge S, (2010) First-generation genomic tests for breast cancer treatment. Lancet Oncol 11: 6–7. doi: 10.1016/S1470-2045(09)70347-X 20005177
27. Cardoso F, Piccart-Gebhart M, Van’t Veer L, Rutgers E, (2007) The mindact trial: the first prospective clinical validation of a genomic tool. Mol Oncol 1: 246–51. doi: 10.1016/j.molonc.2007.10.004 19383299
28. van Wieringen WN, van der Vaart AW, (2011) Statistical analysis of the cancer cell’s molecular entropy using high-throughput data. Bioinformatics 27: 556–63. doi: 10.1093/bioinformatics/btq704 21172912
29. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM, et al. (2005) Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 86: 127–41. doi: 10.1016/j.ygeno.2005.04.008 15950434
30. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346–52. doi: 10.1038/nature10983 22522925
31. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262–72. doi: 10.1093/jnci/djj052 16478745
32. Venet D, Dumont JE, Detours V, (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7: e1002240. doi: 10.1371/journal.pcbi.1002240 22028643
33. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550–5. doi: 10.1073/pnas.0506230102 16141321
34. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953–64. doi: 10.1186/bcr1325 16280042
35. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the transbig multicenter independent validation series. Clin Cancer Res 13: 3207–14. doi: 10.1158/1078-0432.CCR-06-2765 17545524
36. Kao KJ, Chang KM, Hsu HC, Huang AT, (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11: 143. doi: 10.1186/1471-2407-11-143 21501481
37. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239–46. doi: 10.1200/JCO.2006.07.1522 17401012
38. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671–9. doi: 10.1016/S0140-6736(05)70933-8 15721472
39. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529–41. doi: 10.1016/j.ccr.2006.10.009 17157792
40. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405–13. doi: 10.1158/0008-5472.CAN-07-5206 18593943
41. Viale G, Slaets L, Bogaerts J, Rutgers E, van’t Veer L, Piccart-Gebhart MJ, et al. (2014) High concordance of protein (by ihc), gene (by fish; her2 only), and microarray readout (by targetprint) of er, pgr, and her2: results from the eortc 10041/big 03–04 mindact trial. Ann Oncol 25: 816–23. doi: 10.1093/annonc/mdu026 24667714
42. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822–7. doi: 10.1038/nm.1790 18641660
43. Yamauchi M, Yamaguchi R, Nakata A, Kohno T, Nagasaki M, Shimamura T, et al. (2012) Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage i lung adenocarcinoma. PLoS One 7: e43923. doi: 10.1371/journal.pone.0043923 23028479
44. Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, et al. (2013) Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 19: 194–204. doi: 10.1158/1078-0432.CCR-12-1139 23032747
45. Der SD, Sykes J, Pintilie M, Zhu CQ, Strumpf D, Liu N, et al. (2014) Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage ia patients. J Thorac Oncol 9: 59–64. 24305008
46. Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, et al. (2013) Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res 11: 638–50. doi: 10.1158/1541-7786.MCR-12-0634-T 23449933
47. Ein-Dor L, Kela I, Getz G, Givol D, Domany E, (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21: 171–8. doi: 10.1093/bioinformatics/bth469 15308542
48. Michiels S, Koscielny S, Hill C, (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488–92. doi: 10.1016/S0140-6736(05)17866-0 15705458
49. Subramanian J, Simon R, (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102: 464–74. doi: 10.1093/jnci/djq025 20233996
50. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP, (2011) Molecular signatures database (MSigDB) 3.0. Bioinformatics 27: 1739–40. doi: 10.1093/bioinformatics/btr260 21546393
51. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606–11. doi: 10.1073/pnas.1933744100 14500907
52. Gonzalez ME, Moore HM, Li X, Toy KA, Huang W, Sabel MS, et al. (2014) EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci U S A 111: 3098–103. doi: 10.1073/pnas.1308953111 24516139
53. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, et al. (2011) Validation of the histone methyltransferase ezh2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102: 1298–305. doi: 10.1111/j.1349-7006.2011.01958.x 21539681
54. Shao C, Sullivan JP, Girard L, Augustyn A, Yenerall P, Rodriguez-Canales J, et al. (2014) Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. Clin Cancer Res 20: 4154–66. doi: 10.1158/1078-0432.CCR-13-3292 24907115
55. Takahashi-Yanaga F, Kahn M, (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153–62. doi: 10.1158/1078-0432.CCR-09-2943 20530697
56. Buijs JT, van der Horst G, van den Hoogen C, Cheung H, de Rooij B, Kroon J, et al. (2012) The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene 31: 2164–74. doi: 10.1038/onc.2011.400 21996751
57. Marjanovic ND, Weinberg RA, Chaffer CL, (2013) Cell plasticity and heterogeneity in cancer. Clin Chem 59: 168–79. doi: 10.1373/clinchem.2012.184655 23220226
58. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, et al. (2013) Poised chromatin at the zeb1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154: 61–74. doi: 10.1016/j.cell.2013.06.005 23827675
59. Bedard PL, Hansen AR, Ratain MJ, Siu LL, (2013) Tumour heterogeneity in the clinic. Nature 501: 355–64. doi: 10.1038/nature12627 24048068
60. Xie Y, Minna JD, (2012) A lung cancer molecular prognostic test ready for prime time. Lancet 379: 785–7. doi: 10.1016/S0140-6736(12)60154-8 22386017
61. Bilal E, Dutkowski J, Guinney J, Jang IS, Logsdon BA, Pandey G, et al. (2013) Improving breast cancer survival analysis through competition-based multidimensional modeling. PLoS Comput Biol 9: e1003047. doi: 10.1371/journal.pcbi.1003047 23671412
62. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al. (2013) Comparison of pam50 risk of recurrence score with oncotype dx and ihc4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31: 2783–90. doi: 10.1200/JCO.2012.46.1558 23816962
63. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 29: 4273–8. doi: 10.1200/JCO.2010.31.2835 21990413
64. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160–7. doi: 10.1200/JCO.2008.18.1370 19204204
65. Grimmett G, Stirzaker D, (1992) Probability and random processes. Oxford University Press.
66. Demetrius L, Manke T, (2005) Robustness and network evolution-an entropic principle. Physica A: Statistical Mechanics and its Applications 346: 682–696. doi: 10.1016/j.physa.2004.07.011